Elsevier launches Inteleos drug tracking and analysis tool

Supports actionable business decisions for pharmaceutical and biotech professionals

Amsterdam, 27 March 2006 Elsevier, a world-leading healthcare and scientific publisher, announced today the launch of its new drug tracking and analysis tool, Inteleos. To meet the demanding requirements of business intelligence, market research and business development professionals, Elsevier has developed a database of over 8,000 drugs and 1,200 pharmaceutical and biotech companies. The database also includes medical conference news from Elsevier's IMNG, weekly updates from The Pink Sheets, and ontology files of 1.25 million terms to enhance searching.

With Inteleos, users can track and analyse drug activity from late-phase preclinical development through to launch and post-marketing studies. Users can also monitor licensing, or merger and acquisition activities with ease. Inteleos offers a unique combination of features and functionality to help users save valuable time and increase efficiency.

"Our team has shown real commitment to customer focus in bringing Inteleos to market," says Brian Nairn, CEO of Elsevier Health Sciences. "The customer experience is at the core of everything that we do. From the beginning, we've worked to develop tools that enable intelligence professionals to make actionable business decisions. Extensive user testing tells us, Inteleos is doing the job it was designed to do." The Inteleos editorial team adheres to strict editorial guidelines. The database is updated daily using only primary sources direct from drug companies, regulatory agencies, or financial filings.

In addition to breadth and depth of coverage, the Inteleos interface is clean and easy to use. "Users can personalize the search experience with tools that facilitate easy organization and monitoring of drugs, companies and therapy areas," explains Julie Gordon, Director of Emerging Products. "They have the flexibility to run simple or complex searches using a wide set of parameters and the ability to quickly and easily develop graphical representations of scenarios with state-of-the-art analysis tools."

A select group of customers will have immediate access to Inteleos. The database will be available commercially in May 2006.

###

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

You must do the thing you think you cannot do.
~ Eleanor Roosevelt